TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction (DoPING-HFpEF): Rationale and design of a placebo-controlled cross-over intervention study.

被引：0
|
作者：
Van De Bovenkamp, A. A. [1 ]
Bakermans, A. J. [2 ]
Allaart, C. P. [1 ]
Nederveen, A. J. [2 ]
Kok, W. E. M. [3 ]
Van Rossum, A. C. [1 ]
Handoko, M. L. [1 ]
机构：
[1] Amsterdam UMC, Locat VUmc, Cardiol, Amsterdam, Netherlands
[2] Amsterdam UMC, Locat Acad Med Ctr, Radiol & Nucl Med, Amsterdam, Netherlands
[3] Amsterdam UMC, Locat Acad Med Ctr, Clin & Expt Cardiol, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P2022
引用
收藏
页码：357 / 357
页数：1
相关论文
共 36 条
  • [1] TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study
    van de Bovenkamp, A. A.
    Bakermans, A. J.
    Allaart, C. P.
    Nederveen, A. J.
    Kok, W. E. M.
    van Rossum, A. C.
    Handoko, M. L.
    NETHERLANDS HEART JOURNAL, 2020, 28 (06) : 312 - 319
  • [2] TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study
    A. A. van de Bovenkamp
    A. J. Bakermans
    C. P. Allaart
    A. J. Nederveen
    W. E. M. Kok
    A. C. van Rossum
    M. L. Handoko
    Netherlands Heart Journal, 2020, 28 : 312 - 319
  • [3] Results From the DoPING-HFpEF Trial: A Double Blind, Placebo-Controlled Randomized Cross-Over Trial Investigating Trimetazidine in Heart Failure With Preserved Ejection Fraction
    de Bovenkamp, Arno A. Van
    Bakermans, Adrianus J. J.
    Geurkink, Kiki J.
    Oosterveer, Frank T.
    De Man, Frances S.
    Kok, Wouter E.
    Nederveen, Aart J.
    van Rossum, Albert C.
    Handoko, M. Louis L.
    CIRCULATION, 2022, 146
  • [4] Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial
    van de Bovenkamp, Arno A.
    Geurkink, Kiki T. J.
    Oosterveer, Frank T. P.
    de Man, Frances S.
    Kok, Wouter E. M.
    Bronzwaer, Patrick N. A.
    Allaart, Cor P.
    Nederveen, Aart J.
    van Rossum, Albert C.
    Bakermans, Adrianus J.
    Handoko, M. Louis
    ESC HEART FAILURE, 2023, 10 (05): : 2998 - 3010
  • [5] Ubiquinol Improves Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Single Center, Randomized Double-Blind Placebo-Controlled Cross-Over Study
    Kawashima, Chika
    Matsuzawa, Yasushi
    Akiyama, Eiichi
    Sato, Ryosuke
    Konishi, Masaaki
    Suzuki, Hiroyuki
    Kimura, Yuichiro
    Ebina, Toshiaki
    Kosuge, Masami
    Hibi, Kiyoshi
    Iwahashi, Noriaki
    Maejima, Nobuhiko
    Kimura, Kazuo
    CIRCULATION, 2016, 134
  • [6] Ubiquinol Improves Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Single Center, Randomized Double-Blind Placebo-Controlled Cross-Over Study
    Kawashima, Chika
    Matsuzawa, Yasushi
    Akiyama, Eiichi
    Sato, Ryosuke
    Konishi, Masaaki
    Suzuki, Hiroyuki
    Kimura, Yuichiro
    Ebina, Toshiaki
    Kosuge, Masami
    Hibi, Kiyoshi
    Iwahashi, Noriaki
    Maejima, Nobuhiko
    Kimura, Kazuo
    CIRCULATION, 2016, 134
  • [7] Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction
    Desai, Akshay S.
    Lewis, Eldrin F.
    Li, Rebecca
    Solomon, Scott D.
    Assmann, Susan F.
    Boineau, Robin
    Clausell, Nadine
    Diaz, Rafael
    Fleg, Jerome L.
    Gordeev, Ivan
    McKinlay, Sonja
    O'Meara, Eileen
    Shaburishvili, Tamaz
    Pitt, Bertram
    Pfeffer, Marc A.
    AMERICAN HEART JOURNAL, 2011, 162 (06) : 966 - U27
  • [8] Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
    Ali, Danish
    Callan, Nualla
    Ennis, Stuart
    Powell, Richard
    McGuire, Scott
    McGregor, Gordon
    Weickert, Martin O.
    Miller, Michelle A.
    Cappuccio, Francesco P.
    Banerjee, Prithwish
    BMJ OPEN, 2019, 9 (11):
  • [9] Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction
    Zile, Michael R.
    Bourge, Robert C.
    Redfield, Margaret M.
    Zhou, Duo
    Baicu, Catalin F.
    Little, William C.
    JACC-HEART FAILURE, 2014, 2 (02) : 123 - 130
  • [10] Rationale and design for a multicenter, randomized, double-blind, placebo- controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
    Udelson, James E.
    Lewis, Gregory D.
    Shah, Sanjiv J.
    Zile, Michael R.
    Redfield, Margaret M.
    Burnett, John, Jr.
    Mittleman, Robert S.
    Profy, Albert T.
    Seferovic, Jelena P.
    Reasner, David
    Konstam, Marvin A.
    AMERICAN HEART JOURNAL, 2020, 222 : 183 - 190
1234